Neurosense Therapeutics Stock Widgets and Gadgets
| NRSN Stock | USD 0.86 0.07 7.53% |
| Intraday Equity Chart Quick Equity Feed Equity Search Quote Ticker Widgets Data Sheet |
Live Stock Ticker Example
- NRSN Neurosense Therapeutics
- Latest Financial Analysis Emmaus Life Sciences versus NeuroSense Therapeutics
- NRSN 0.86 -0.07
- Low 0.81
- High 0.94
- Alpha -0.59
- Beta 0.81
- Return On Equity -4.95
- Return On Asset -1.51
- Current Valuation 18.72 M
- Shares Outstanding 23.13 M
- Shares Owned By Insiders 35.03 %
- Shares Owned By Institutions 1.08 %
- Number Of Shares Shorted 324.35 K
- Price To Book 4.15 X
- EBITDA (10.63 M)
- Net Income (11.28 M)
- Cash And Equivalents 10.37 M
- Cash Per Share 0.89 X
- Total Debt 142 K
- Debt To Equity 0.02 %
- Current Ratio 15.09 X
- Book Value Per Share (0.09) X
- Cash Flow From Operations (8.45 M)
- Short Ratio 2.01 X
- Earnings Per Share (0.65) X
- Target Price 5.25
- Number Of Employees 18
- Beta 1.57
- Market Capitalization 19.89 M
- Total Asset 3.18 M
- Retained Earnings (32.07 M)
- Working Capital (543 K)
- Net Asset 3.18 M
- Accumulation Distribution 0.14
- Daily Balance Of Power (0.54)
- Rate Of Daily Change 0.92
- Day Median Price 0.88
- Day Typical Price 0.87
- Market Facilitation Index 0.13
- Price Action Indicator (0.05)
- Period Momentum Indicator (0.07)
- Relative Strength Index 17.05
Market Snapshot Widget Example
DAX Index Germany | 20,406 0.1 | |
Taiwan Weighted Taiwan | 23,020 0.11 | |
PSI 20 Stock Portugal | 6,354 0.11 | |
CROBEX Croatia | 3,194 0.13 | |
Budapest SE Hungary | 80,166 0.46 | |
IDX 30 Jakarta Indonesia | 443.33 1.05 | |
ISEQ 20 Price Ireland | 1,648 0.0006 | |
NYSE Comp USA | 19,729 0.2 | |
Tel Aviv 35 Israel | 2,335 0.04 | |
Coreshares Index Tracker South Afric | 1,098 1.29 | |
IPC MEXICO Mexico | 51,653 0.06 | |
KL Technology Malaysia | 63.70 2.18 | |
IBEX 35 Index Spain | 11,752 0.11 | |
SP Merval Argentina | 1,000,000 0.00 | |
Austrian Traded Index Austria | 3,648 0.28 | |
SPASX Dividend Opportunities Australia | 1,680 0.49 | |
HNX 30 Vietnam | 480.47 0.88 | |
Bucharest BET-NG Romania | 1,247 0.38 | |
AMS Small Cap Netherlands | 1,240 0.14 | |
Oslo Exchange Mutual Norway | 1,405 0.14 | |
BEL Small Belgium | 8,042 0.12 | |
Basic Materials Brazil | 5,772 2.08 | |
Swiss Leader Price Switzerland | 1,938 0.22 | |
Fondo Mutuo ETF Chile | 1,408 0.51 | |
Athens General Comp Greece | 1,469 0.36 | |
Stock Exchange Of Thailand | 1,432 0.57 | |
PX Prague Stock Czech Repub | 1,749 0.60 | |
THE PHILIPPINE STOCK Philippines | 6,617 0.37 | |
WIG 30 Poland | 2,896 0.14 | |
BIST Electricity Turkey | 514.73 0.73 |
Investing Ideas
In addition to having Neurosense Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Thematic Opportunities
Explore Investment Opportunities
Compare Neurosense Therapeutics
Compare Neurosense Therapeutics To Peers
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.